NextCure, Inc., a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, reported a net loss of $55.8 million for the fiscal year ending December 31, 2025, a slight increase from a loss of $55.7 million in the previous year. The company's accumulated deficit now stands at $436 million. Total operating expenses for 2025 were $57.6 million, down from $59.7 million in 2024, primarily due to a reduction in general and administrative costs. Research and development expenses increased by 8% to $44.9 million, driven largely by costs associated with the development of its lead product candidate, SIM0505, which accounted for $20.4 million in expenses.
In terms of strategic developments, NextCure entered into a significant License Agreement with Simcere Zaiming Pharmaceutical Co., Ltd. in June 2025, acquiring global rights to develop and commercialize the ADC candidate SIM0505. This agreement includes milestone payments that could total up to $166.5 million per product, along with tiered royalties on net sales. The company also announced a restructuring plan in March 2024, which included pausing internal manufacturing operations and reducing its workforce by approximately 37%. As of December 31, 2025, NextCure had 40 full-time employees.
NextCure's clinical pipeline includes two primary candidates: SIM0505, which is currently in Phase 1 clinical trials for multiple solid tumors, and LNCB74, another ADC targeting B7-H4, which is also in Phase 1 trials. The company expects to provide updates on both candidates in 2026. As of the end of 2025, NextCure had cash, cash equivalents, and marketable securities totaling $41.8 million, which management believes will fund operations into the first half of 2027. However, the company has expressed substantial doubt about its ability to continue as a going concern without raising additional capital.
Looking ahead, NextCure plans to focus on advancing its clinical programs and is actively seeking partnerships or third-party financing to support its preclinical non-oncology programs. The company acknowledges the need for substantial additional funding to continue its operations and development strategy, which may include public or private equity offerings, debt financing, or collaborations. The success of its product candidates will depend on various factors, including the completion of clinical trials, regulatory approvals, and market acceptance.
About NextCure, Inc.
NextCure, Inc. is a clinical-stage biopharmaceutical company developing innovative cancer therapies, primarily antibody-drug conjugates (ADCs). Its lead candidate, LNCB74, targets B7-H4, a tumor-associated protein, for cancers like breast and ovarian. The company also explores non-oncology programs, collaborates with LigaChem and Yale, and focuses on advancing targeted biologics through research, development, and strategic partnerships.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.